1vyf: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==schistosoma mansoni fatty acid binding protein in complex with oleic acid== | ==schistosoma mansoni fatty acid binding protein in complex with oleic acid== | ||
<StructureSection load='1vyf' size='340' side='right' caption='[[1vyf]], [[Resolution|resolution]] 1.85Å' scene=''> | <StructureSection load='1vyf' size='340' side='right'caption='[[1vyf]], [[Resolution|resolution]] 1.85Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1vyf]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Blood_fluke Blood fluke]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1VYF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1VYF FirstGlance]. <br> | <table><tr><td colspan='2'>[[1vyf]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Blood_fluke Blood fluke]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1VYF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1VYF FirstGlance]. <br> | ||
Line 29: | Line 29: | ||
==See Also== | ==See Also== | ||
*[[Fatty acid-binding protein|Fatty acid-binding protein]] | *[[Fatty acid-binding protein 3D structures|Fatty acid-binding protein 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
Line 35: | Line 35: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Blood fluke]] | [[Category: Blood fluke]] | ||
[[Category: Large Structures]] | |||
[[Category: Angelucci, F]] | [[Category: Angelucci, F]] | ||
[[Category: Baiocco, P]] | [[Category: Baiocco, P]] |
Revision as of 13:36, 8 January 2020
schistosoma mansoni fatty acid binding protein in complex with oleic acidschistosoma mansoni fatty acid binding protein in complex with oleic acid
Structural highlights
Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedSchistosoma mansoni fatty acid binding protein (Sm14) was crystallized with bound oleic acid (OLA) and arachidonic acid (ACD), and their structures were solved at 1.85 and 2.4 A resolution, respectively. Sm14 is a vaccine target for schistosomiasis, the second most prevalent parasitic disease in humans. The parasite is unable to synthesize fatty acids depending on the host for these nutrients. Moreover, arachidonic acid (ACD) is required to synthesize prostaglandins employed by schistosomes to evade the host's immune defenses. In the complex, the hydrocarbon tail of bound OLA assumes two conformations, whereas ACD adopts a unique hairpin-looped structure. ACD establishes more specific interactions with the protein, among which the most important is a pi-cation bond between Arg78 and the double bond at C8. Comparison with homologous fatty acid binding proteins suggests that the binding site of Sm14 is optimized to fit ACD. To test the functional implications of our structural data, the affinity of Sm14 for 1,8-anilinonaphthalenesulfonic acid (ANS) has been measured; moreover the binding constants of six different fatty acids were determined from their ability to displace ANS. OLA and ACD exhibited the highest affinities. To determine the rates of fatty acid binding and dissociation we carried out stopped flow kinetic experiments monitoring displacement by (and of) ANS. The binding rate constant of ligands is controlled by a slow pH dependent conformational change, which we propose to have physiological relevance. Schistosoma mansoni fatty acid binding protein: specificity and functional control as revealed by crystallographic structure.,Angelucci F, Johnson KA, Baiocco P, Miele AE, Brunori M, Valle C, Vigorosi F, Troiani AR, Liberti P, Cioli D, Klinkert MQ, Bellelli A Biochemistry. 2004 Oct 19;43(41):13000-11. PMID:15476393[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|